|
DK172110B1
(da)
|
1988-04-15 |
1997-10-27 |
Gen Hospital Corp |
Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
|
|
US5006309A
(en)
|
1988-04-22 |
1991-04-09 |
Abbott Laboratories |
Immunoassay device with liquid transfer between wells by washing
|
|
US5089424A
(en)
|
1988-06-14 |
1992-02-18 |
Abbott Laboratories |
Method and apparatus for heterogeneous chemiluminescence assay
|
|
US5063081A
(en)
|
1988-11-14 |
1991-11-05 |
I-Stat Corporation |
Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
|
|
CA2069530A1
(en)
|
1991-06-03 |
1992-12-04 |
Cass J. Grandone |
Reagent pack for immunoassays
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
IL119586A
(en)
|
1996-11-07 |
2001-09-13 |
Univ Ramot |
Discontinuous library of a single biological unit and a method for its preparation
|
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
|
ES2252261T3
(es)
|
2000-06-28 |
2006-05-16 |
Glycofi, Inc. |
Metodos para producir glicoproteinas modificadas.
|
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
|
KR20030074693A
(ko)
|
2000-12-28 |
2003-09-19 |
알투스 바이올로직스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
|
CA2451998A1
(en)
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
Anti-a.beta. antibodies
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US7419821B2
(en)
|
2002-03-05 |
2008-09-02 |
I-Stat Corporation |
Apparatus and methods for analyte measurement and immunoassay
|
|
US20040018577A1
(en)
|
2002-07-29 |
2004-01-29 |
Emerson Campbell John Lewis |
Multiple hybrid immunoassay
|
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
AR045056A1
(es)
|
2003-07-15 |
2005-10-12 |
Amgen Inc |
Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
WO2005035575A2
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
|
US7723099B2
(en)
|
2003-09-10 |
2010-05-25 |
Abbott Point Of Care Inc. |
Immunoassay device with immuno-reference electrode
|
|
US7682833B2
(en)
|
2003-09-10 |
2010-03-23 |
Abbott Point Of Care Inc. |
Immunoassay device with improved sample closure
|
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
|
US20050250185A1
(en)
|
2003-12-12 |
2005-11-10 |
Murphy Andrew J |
OGH fusion polypeptides and therapeutic uses thereof
|
|
PT1730191E
(pt)
|
2004-03-30 |
2011-10-04 |
Glaxo Group Ltd |
Imunoglobulina que se liga a hosm
|
|
BRPI0510716A
(pt)
|
2004-05-05 |
2007-11-20 |
Merrimack Pharmaceuticals Inc |
uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
|
|
FR2873699B1
(fr)
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
|
AU2006218876A1
(en)
|
2005-02-28 |
2006-09-08 |
Centocor, Inc. |
Heterodimeric protein binding compositions
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
MX2008000985A
(es)
|
2005-07-21 |
2008-04-07 |
Abbott Lab |
Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
EP1963368B3
(en)
|
2005-12-13 |
2020-06-10 |
Eli Lilly And Company |
Anti-il-17 antibodies
|
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
EP2238170B1
(en)
|
2008-01-31 |
2016-11-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
KR20100135780A
(ko)
|
2008-03-06 |
2010-12-27 |
제넨테크, 인크. |
Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
BRPI0914916A2
(pt)
|
2008-06-30 |
2015-10-20 |
Novo Nordisk As |
anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
|
|
CA2756244A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
SG175077A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
EP2478373B1
(en)
|
2009-09-14 |
2019-01-09 |
Icahn School of Medicine at Mount Sinai |
Methods for characterizing antibody binding affinity and epitope diversity in food allergy
|
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
CN103068847B
(zh)
|
2010-08-24 |
2019-05-07 |
罗切格利卡特公司 |
可活化的双特异性抗体
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
PE20141060A1
(es)
|
2010-12-21 |
2014-09-26 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
|
|
EP2654789B1
(en)
|
2010-12-22 |
2018-05-30 |
Orega Biotech |
Antibodies against human cd39 and use thereof
|
|
EP2683735A1
(en)
|
2011-03-10 |
2014-01-15 |
HCO Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
|
NO2748201T3
(enExample)
|
2011-08-23 |
2018-05-12 |
|
|
|
CA2861003C
(en)
|
2012-01-13 |
2023-03-28 |
Julius-Maximilians-Universitat Wurzburg |
Dual antigen-induced bipartite functional complementation
|
|
WO2013150043A1
(en)
|
2012-04-05 |
2013-10-10 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
JP2016514676A
(ja)
|
2013-03-15 |
2016-05-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
四価二重特異性抗体
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
RU2652880C2
(ru)
|
2013-04-07 |
2018-05-03 |
Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. |
Антитело против рецептора эпидермального фактора роста
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
KR102089591B1
(ko)
|
2013-07-29 |
2020-03-18 |
삼성전자주식회사 |
항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
|
|
EP3079698A1
(en)
|
2013-12-12 |
2016-10-19 |
Novartis AG |
Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
|
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
PE20170255A1
(es)
*
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
KR101971770B1
(ko)
|
2014-03-03 |
2019-04-24 |
아카데미아 시니카 |
이중특이성 항체 및 이의 용도
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
|
WO2015176033A1
(en)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
US10092645B2
(en)
|
2014-06-17 |
2018-10-09 |
Medimmune Limited |
Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
|
|
EP3177643B1
(en)
|
2014-08-04 |
2019-05-08 |
F.Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
JO3663B1
(ar)
*
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
EP3701969A1
(en)
|
2014-10-31 |
2020-09-02 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
|
EP3215538A4
(en)
|
2014-11-07 |
2018-07-04 |
Igenica Biotherapeutics, Inc. |
Anti-cd39 antibodies and uses thereof
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
GB201500319D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
TWI773646B
(zh)
*
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
HUE068868T2
(hu)
*
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
WO2017024515A1
(en)
*
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
|
IL300122A
(en)
|
2015-11-18 |
2023-03-01 |
Merck Sharp ַ& Dohme Llc |
Substances that bind to PD1 and/or LAG3
|
|
CA3005986A1
(en)
|
2015-11-23 |
2017-06-01 |
Innate Pharma |
Cd39 vascular isoform targeting agents
|
|
WO2017132827A1
(en)
*
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
US11421028B2
(en)
|
2016-02-06 |
2022-08-23 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
TWI910495B
(zh)
*
|
2016-05-13 |
2026-01-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
HRP20210602T1
(hr)
|
2016-06-20 |
2021-05-14 |
F-Star Delta Limited |
Vezujuće molekule koje vežu pd-l1 i lag-3
|
|
CN114456269A
(zh)
*
|
2016-09-21 |
2022-05-10 |
基石药业（苏州）有限公司 |
一种新的pd-1单克隆抗体
|
|
PH12019500668B1
(en)
|
2016-10-13 |
2023-12-06 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Anti-lag-3 antibodies and compositions
|
|
EP3565833A1
(en)
|
2017-01-09 |
2019-11-13 |
Torch Therapeutics |
Conditionally effective bispecific therapeutics
|
|
MY202018A
(en)
|
2017-07-31 |
2024-03-29 |
Trishula Therapeutics Inc |
Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
|
|
BR112020006809A2
(pt)
|
2017-10-06 |
2020-10-06 |
Innate Pharma |
anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso
|
|
KR102781619B1
(ko)
|
2017-11-15 |
2025-03-14 |
이나뜨 파르마 에스.에이. |
암의 치료를 위한 인간 CD39 단백질의 ATPase 활성을 결합 및 저해하는 항체
|
|
BR112022002067A2
(pt)
|
2019-08-08 |
2022-06-14 |
Regeneron Pharma |
Formatos de molécula de ligação ao antígeno
|